I already received my parcel, I had a problem as the courier wanted to deliver
to my home as they claim they cannot place the order into my postbox. This was
my preferred option.
There is not someone at home always, so we had to get the parcel to my office.
No problem with that.
I did have an enquiry into the 4 extra pills, and this was delivered within a
few days via airmail to my post box.
I would suggest you attend to this part of your process as the extra cost is
unnecessary. Include everything into one parcel.
All in all, good service.
- Jan
New Therapies for Prostate Cancer: The Practicalities - OncLive
OncLiveNew Therapies for Prostate Cancer: The PracticalitiesOncLive12,13 This investigational agent is an irreversible androgen receptor (AR) antagonist and AR signaling inhibitor, and represents an advance from the nonsteroidal AR antagonists flutamide, bicalutamide, and nilutamide.
Medivation Reports First Quarter Financial Results and Provides Corporate Update - MarketWatch (press release)
Medivation Reports First Quarter Financial Results and Provides Corporate UpdateMarketWatch (press release)Continued to enroll patients in the Phase 2 TERRAIN trial, which is comparing the effect of enzalutamide versus bicalutamide, the most commonly used anti-androgen, on progression-free survival in approximately 370 men with advanced prostate cancer who .
MDVN Misses; Focus on Enzalutamide - Zacks.com
MDVN Misses; Focus on EnzalutamideZacks.
MDVN Misses; Focus on Enzalutamide - Analyst Blog - NASDAQ
MDVN Misses; Focus on Enzalutamide - Analyst BlogNASDAQEnzalutamide is also in a phase II study (TERRAIN), which will compare enzalutamide with bicalutamide, in advanced prostate cancer patients who have progressed following medical castration with LHRH analog therapy or surgical castration.
CEO Brennan to leave AstraZeneca as profits sink - Pharma Times
CEO Brennan to leave AstraZeneca as profits sinkPharma TimesAs for oncology, Arimidex (anastrozole) fell 39% to $144 million, battered by patent expiries, while Casodex (bicalutamide) fell 17% to $113 million.